Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4513 Predictive value of different PD-L1 immunohistochemistry clones for immunotherapy efficacy in neuroendocrine tumours: A case series

Introduction: In the ZS001 clinical trial, we observed that NET patients with higher PD-L1 expression levels were more likely to benefit preferentially from immunotherapy.

Conference:

Presenting Author:

Authors: Sun Y, Zhang Q, Cao F, Huang X, Zhang P,

Keywords: neuroendocrine tumour, immunotherapy, PD-L1, SP142, 28-8, C0148, E1L3N,

#4406 Fluorescence labelled plasma derived small extracellular vesicle as biomarkers in metastatic pancreatic neuroendocrine tumour patients

Introduction: Pancreatic neuroendocrine tumours (PanNET) are rare with increased annual incidence rate 1/lac. There are no specific biomarkers, diagnostic and prognostic tests available for PanNET. The small extracellular vesicles (sEV) play a key role in tumour growth and metastasis and can be a potential biomarker for metastasis of PanNET.

Conference:

Presenting Author:

Authors: As S, Gorai P, Naik M, Kumar R, Kumar S,

Keywords: Metastasis, Pancreatic neuroendocrine tumour, Small extracellular vesicles, Fluorescence, Nanoparticle tracking analysis,

#4307 Predictive value of pepsinogen I and I/II ratio for diagnosing autoimmune gastritis

Introduction: Autoimmune gastritis (AIG) is sometimes difficult to diagnose.

Conference:

Presenting Author:

Authors: Hu H, Chen C, Zhang Q, Li P,

Keywords: autoimmune gastritis, pepsinogen 1, pepsinogen 1/2 ratio, gastrin,

#4282 A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumours and carcinomas

Introduction: Neuroendocrine neoplasms (NENs) consist of neuroendocrine tumours and neuroendocrine carcinomas, which are rare malignancies found in various anatomical sites, including the gastrointestinal tract, pancreatic islets, lungs, and adrenal glands. Poorly differentiated NECs are classified as high-grade carcinomas that bear resemblance to small-cell lung cancer; however, these patients experience a high risk of relapse and demonstrate a limited response to additional systemic therapies. Adrenocortical carcinoma (ACC) is another rare cancer and currently, no targeted therapies have demonstrated significant effectiveness for this condition. Preclinical investigations have indicated that Delta-like non-canonical notch ligand 1 (DLK1) is expressed in various neuroendocrine neoplasms, including ACC, SCLC, neuroblastoma, pheochromocytoma, and paraganglioma.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Glod J, Magee T, Cooper K, Rivero A,

Keywords: NEN, NEC, NET, ACC, ADC, ADCT-701,